High impact
Enhertu (fam-trastuzumab deruxtecan-nxki)
Humana·Effective Jun 1, 2026
Humana Indiana Medicaid has established a new prior authorization policy for Enhertu (fam-trastuzumab deruxtecan-nxki) effective June 1, 2026, covering seven oncologic indications including HER2-positive, HER2-low, and HER2-ultralow breast cancers, gastric/GEJ adenocarcinoma, HER2-mutant NSCLC, and HER2-positive solid tumors. All uses require prior authorization with specific clinical criteria that must be met for approval, including prior treatment requirements and monotherapy or combination restrictions.